Identification of N-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H-pyrazole-3-carboxamide (AT7519), a novel cyclin dependent kinase inhibitor using fragment-based X-ray crystallography and structure based drug design

TY - JOUR

T1 - Identification of N-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H-pyrazole-3-carboxamide (AT7519), a novel cyclin dependent kinase inhibitor using fragment-based X-ray crystallography and structure based drug design

AU - Wyatt, Paul G.

AU - Woodhead, Andrew J.

AU - Berdini, Valerio

AU - Boulstridge, John A.

AU - Carr, Maria G.

AU - Cross, David M.

AU - Davis, Deborah J.

AU - Devine, Lindsay A.

AU - Early, Theresa R.

AU - Feltell, Ruth E.

AU - Lewis, E. Jonathan

AU - McMenamin, Rachel L.

AU - Navarro, Eva F.

AU - O'Brien, Michael A.

AU - O'Reilly, Marc

AU - Reule, Matthias

AU - Saxty, Gordon

AU - Seavers, Lisa C. A.

AU - Smith, Donna-Michelle

AU - Squires, Matt S.

AU - Trewartha, Gary

AU - Walker, Margaret T.

AU - Woolford, Alison J. -A.

PY - 2008/8/28

Y1 - 2008/8/28

N2 - The application of fragment-based screening techniques to cyclin dependent kinase 2 (CDK2) identified multiple (> 30) efficient, synthetically tractable small molecule hits for further optimization. Structure-based design approaches led to the identification of multiple lead series, which retained the key interactions of the initial binding fragments and additionally explored other areas of the ATP binding site. The majority of this paper details the structure-guided optimization of indazole (6) using information gained from multiple ligand-CDK2 cocrystal structures. Identification of key binding features for this class of compounds resulted in a series of molecules with low nM affinity for CDK2. Optimisation of cellular activity and characterization of pharmacokinetic properties led to the identification of 33 (AT7519), which is currently being evaluated in clinical trials for the treatment of human cancers.

AB - The application of fragment-based screening techniques to cyclin dependent kinase 2 (CDK2) identified multiple (> 30) efficient, synthetically tractable small molecule hits for further optimization. Structure-based design approaches led to the identification of multiple lead series, which retained the key interactions of the initial binding fragments and additionally explored other areas of the ATP binding site. The majority of this paper details the structure-guided optimization of indazole (6) using information gained from multiple ligand-CDK2 cocrystal structures. Identification of key binding features for this class of compounds resulted in a series of molecules with low nM affinity for CDK2. Optimisation of cellular activity and characterization of pharmacokinetic properties led to the identification of 33 (AT7519), which is currently being evaluated in clinical trials for the treatment of human cancers.

UR - https://www.scopus.com/pages/publications/50249083873

U2 - 10.1021/jm800382h

DO - 10.1021/jm800382h

M3 - Article

SN - 0022-2623

VL - 51

SP - 4986

EP - 4999

JO - Journal of Medicinal Chemistry

JF - Journal of Medicinal Chemistry

IS - 16

ER -